Visceral Fat Area and Subcutaneous Fat Area Increase in Hyperthyroidism Patients After Treatment—A Single-Group Repeated-Measures Trial
Mengnan Li,Xifeng Yang,Ru Li,Baofeng Wu,Jinxuan Hao,Yijie Qi,Tao Bai,Luyang Yang,Yi Zhang,Yunfeng Liu
DOI: https://doi.org/10.2147/dmso.s458486
2024-05-28
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Mengnan Li, 1, 2, &ast Xifeng Yang, 1, 2, &ast Ru Li, 1, 2 Baofeng Wu, 1, 2 Jinxuan Hao, 1, 2 Yijie Qi, 1, 2 Tao Bai, 1 Luyang Yang, 1 Yi Zhang, 3 Yunfeng Liu 1, 4 1 Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China; 2 First Clinical Medical College, Shanxi Medical University, Taiyuan, People's Republic of China; 3 Department of Pharmacology, Shanxi Medical University, Taiyuan, People's Republic of China; 4 Clinical Research Center of Endocrine and Metabolic Diseases in Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yunfeng Liu, Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China, Email Yi Zhang, Department of Pharmacology, Shanxi Medical University, Taiyuan, People's Republic of China, Email Purpose: There is evidence that long-term vascular risk remains increased in patients with hyperthyroidism even after normalization of thyroid function, and the mechanisms that regulate this risk are unclear. The aim of this study was to assess how visceral fat area and subcutaneous fat area change after hyperthyroidism treatment, and to further explore the relationship between thyroid hormones, abdominal fat area (visceral fat area and subcutaneous fat area), and lipids. Patients and Methods: 50 patients with newly diagnosed Graves' disease were selected. Anthropometric parameters (weight, height, body mass index, waist circumference, neck circumference), laboratory parameters (thyroid hormones, lipid metabolism indices), abdominal fat area (visceral fat area and subcutaneous fat area), and drug dose were collected. Measurements were made at baseline, 6 and 12 months after treatment. We used linear mixed-effects models for analysis. Results: The results showed that the following indexes changed significantly at different time points: visceral fat area, subcutaneous fat area, free triiodothyronine, free thyroxine, thyroid stimulating hormone, total cholesterol, high-density lipoprotein, low-density lipoprotein, body weight, neck circumference, body mass index, waist circumference, and drug dose (All P< 0.001). We found that free triiodothyronine and free thyroxine were significantly negatively associated with abdominal fat area (P 0.05). Total cholesterol and low-density lipoprotein were significantly positively associated with abdominal fat area (P< 0.01). However, high-density lipoprotein (P=0.06) was not correlated with abdominal fat area. Moreover, the results showed a significant negative correlation between thyroid hormones and lipids (P< 0.001). Conclusion: After anti-thyroid medicine treatment, patients had elevated visceral fat area and subcutaneous fat area and altered lipid profiles. These changes may be one of the reasons why metabolic and cardiovascular diseases remain increased after thyroid function is restored. Keywords: visceral fat area, subcutaneous fat area, thyroid hormones, lipids, Graves' disease The incidence of hyperthyroidism is on the rise, and the age of onset is gradually advancing. Graves' disease (GD) is the most common type of hyperthyroidism, and its pathogenesis is complex. The thyroid stimulating hormone (TSH) receptor antibody is the ultimate cause of GD. These antibodies bind to TSH receptors on the surface of thyroid follicular cells, resulting in excessive secretion of thyroid hormones (THs) and increased multisystem excitability and hypermetabolism. 1 The typical manifestation of hyperthyroidism is palpitation, shaking hands, fatigue, a strong appetite but weight loss, and other symptoms. For patients with hyperthyroidism, anti-thyroid drugs (especially methimazole) are the main choice of treatment at present. 2 Most of the above symptoms will be relieved after treatment of hyperthyroidism. Studies have clearly shown a significant increase in cardiovascular morbidity and mortality in patients with hyperthyroidism because thyroid receptors are also present on cardiomyocytes and vascular endothelial cells and are sensitive to changes in the concentration of THs. 3 Overproduction of THs can lead to increased heart rate, a hyperdynamic state of circulation, and even cardiovascular disease (CVD) such as atrial fibrillation. 4 These changes are reversible with regular treatment. However, there is -Abstract Truncated-
endocrinology & metabolism